Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
Top Cited Papers
- 8 January 2013
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 14 (2), 149-158
- https://doi.org/10.1016/s1470-2045(12)70560-0
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401Journal of Clinical Oncology, 2012
- A phase III trial of docetaxel–estramustine in high-risk localised prostate cancer: A planned analysis of response, toxicity and quality of life in the GETUG 12 trialEuropean Journal Of Cancer, 2012
- Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 StudyJournal of Clinical Oncology, 2011
- Castration-Dependent Pharmacokinetics of Docetaxel in Patients With Prostate CancerJournal of Clinical Oncology, 2010
- The estimation of average hazard ratios by weighted Cox regressionStatistics in Medicine, 2009
- Prostate-Specific Antigen Progression Predicts Overall Survival in Patients With Metastatic Prostate Cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916Journal of Clinical Oncology, 2009
- Phase II Trial of Docetaxel With Rapid Androgen Cycling for Progressive Noncastrate Prostate CancerJournal of Clinical Oncology, 2008
- Docetaxel, Estramustine, and 15-Month Androgen Deprivation for Men With Prostate-Specific Antigen Progression After Definitive Local Therapy for Prostate CancerJournal of Clinical Oncology, 2006
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Proportional hazards tests and diagnostics based on weighted residualsBiometrika, 1994